Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of ASP6282 in Healthy Subjects
NCT02420782Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ASP6282 in underactive bladder (UAB) (10 arms), sponsored by Astellas Pharma. Primary endpoints: Safety as assessed by adverse events, Safety as assessed by vital signs and 2 more. Started May 2015; status: completed.
02
Drugs
ASP6282
03
Conditions
underactive bladder (UAB)
Beyond the preview
Go deeper on NCT02420782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420782.